NEW YORK, NY, UNITED STATES, May 15, 2025 / EINPresswire.com / -- Ace Therapeutics, a leading IBD research service company, revealed its novel IBD animal models, created to bridge the complex ...

- Data reveal WTX-921 is efficacious in a mouse colitis model, resulting in reduced tissue damage and inflammatory cytokine production - - Findings offer a more detailed understanding of WTX-921’s ...

Thetis Pharmaceuticals LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, small molecule drug candidate targeting the BLT1 receptor to treat inflammatory bowel disease (IBD) ...

Abivax is actively conducting preclinical studies with multiple oral and injectable therapies and will report additional data in Q4 2024. Pre-clinical evaluation of obefazimod combined with etrasimod ...

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Breadth of Scientific ...

Specific protein signatures can predict Crohn's disease and ulcerative colitis, enabling early intervention in IBD. The study identified 34 proteins for Crohn's disease and 45 for ulcerative colitis, ...

At the United European Gastroenterology Week in Vienna, Redx Pharma plc presented data regarding their ROCK inhibitor RXC-008 for treating fibrostenotic Crohn’s disease. RXC-008 is restricted to the ...